8-K: Karyopharm Therapeutics Announces Trial Results and FDA Plans

Karyopharm Therapeutics reported topline data from its XPORT-EC-042 trial for endometrial cancer, which did not meet its primary endpoint, but also announced plans for a myelofibrosis sNDA submission.

Summary

• Karyopharm Therapeutics announced topline results from the Phase 3 XPORT-EC-042 trial for advanced or recurrent endometrial cancer, which did not meet its primary endpoint of progression-free survival (PFS).
• In the mITT population (n=236), a trend favoring selinexor showed a median PFS of 12.75 months versus 7.43 months for placebo (HR=0.76).
• The safety profile of selinexor was consistent with previous findings, with no new safety signals.
• The company plans to submit a supplemental New Drug Application (sNDA) to the FDA in August 2026 for accelerated approval of selinexor in combination with ruxolitinib for myelofibrosis.
• This submission is based on productive FDA engagements where spleen volume reduction (SVR35) is considered a qualifying surrogate endpoint for accelerated approval.
• The company is exploring potential financing transactions and strategic alternatives to extend its cash runway and maximize stakeholder value.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the failure to meet the primary endpoint in a key trial, despite positive developments in another indication and strategic exploration.

Positives

• A trend favoring selinexor was observed in the modified intent-to-treat (mITT) population for PFS in the XPORT-EC-042 trial, with a median PFS of 12.75 months compared to 7.43 months for placebo.
• The safety and tolerability profile of selinexor in the XPORT-EC-042 trial was consistent with its established profile, with no new safety signals.
• The FDA has indicated that spleen volume reduction (SVR35) appears to qualify as a reasonably likely surrogate endpoint to predict overall survival for the myelofibrosis indication.
• The company plans to request Priority Review for the myelofibrosis sNDA, which could lead to a Prescription Drug User Fee Act target action date approximately six months after FDA receipt.

Negatives

• The Phase 3 XPORT-EC-042 trial evaluating selinexor as maintenance-only therapy for endometrial cancer did not meet its primary endpoint of progression-free survival (PFS).
• The FDA requires further discussion on the data to be used to support the myelofibrosis sNDA and convert potential accelerated approval to traditional approval.

Risks

• The Company's ability to successfully consummate a financing transaction or execute on a strategic alternative is dependent on a number of factors, with no assurance of any transaction.
• Substantial doubt exists regarding the Company's ability to continue as a going concern.
• There can be no guarantee that the Company will successfully commercialize XPOVIO or that any of its drug candidates will successfully complete clinical development.
• The content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities could impact development timelines.
• Competitors may develop or gain regulatory approval for drug candidates for products or product candidates in which Karyopharm is currently commercializing or developing.

Future Outlook

The Company is exploring potential financing transactions and strategic alternatives to extend its cash runway. The Company plans to submit an sNDA for selinexor in combination with ruxolitinib for myelofibrosis in August 2026, seeking accelerated approval. The Company intends to request Priority Review for this submission. The Company also intends to present data from the XPORT-EC-042 trial at a future medical meeting.

Management Comments

• The Company intends to complete a full evaluation of the data from the XPORT-EC-042 trial and plans to present the data at a future medical meeting.
• The Company intends to address the FDAs requests and provide the FDA with additional data and information prior to the submission of the sNDA in August 2026.
• The Company, with the assistance of its advisors, including its financial advisor Centerview Partners, is exploring potential financing transactions to extend its cash runway along with strategic alternatives in order to maximize both near and long-term value for all stakeholders.
• There is no assurance that these efforts will result in any type of transaction or, if they do, what the ultimate terms of any such transaction would be.
• The Company does not intend to discuss or disclose further developments unless and until its Board of Directors has approved a specific transaction or the Company otherwise determines that further disclosure is appropriate.

Industry Context

StockSavvy.ai notes that Karyopharm Therapeutics is navigating a critical period, with mixed clinical trial results for its lead candidate selinexor. The failure to meet the primary endpoint in the endometrial cancer trial presents a setback, while the planned myelofibrosis sNDA submission highlights ongoing efforts to leverage the drug's potential in other indications. The company's exploration of strategic alternatives underscores the financial pressures often faced by biopharmaceutical companies during drug development.

Stakeholder Impact

• Shareholders may be impacted by the negative trial results and the ongoing exploration of strategic alternatives, which could lead to dilution or a change in company direction.
• Patients with endometrial cancer may not benefit from selinexor as a maintenance-only therapy as initially hoped.
• Patients with myelofibrosis may benefit from the potential accelerated approval of selinexor in combination with ruxolitinib, pending FDA review.

Next Steps

• Complete full evaluation of data from the XPORT-EC-042 trial.
• Present data from the XPORT-EC-042 trial at a future medical meeting.
• Submit a supplemental New Drug Application (sNDA) to the FDA for selinexor in combination with ruxolitinib for myelofibrosis in August 2026.
• Address FDA requests and provide additional data for the myelofibrosis sNDA submission.
• Explore potential financing transactions and strategic alternatives.

Key Dates

Recommendation

The mixed results from the XPORT-EC-042 trial are a significant negative, failing to meet the primary endpoint. However, the planned sNDA submission for myelofibrosis, supported by FDA feedback on surrogate endpoints, offers a potential positive catalyst. The exploration of strategic alternatives adds uncertainty. Given these competing factors, a 'hold' recommendation is appropriate pending further clarity on the myelofibrosis submission and the outcome of strategic explorations.

Keywords

selinexor, endometrial cancer, myelofibrosis, clinical trial, FDA submission, accelerated approval, progression-free survival, spleen volume reduction